Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist inhibits transforming growth factor-beta1 and matrix production in human dermal fibroblasts

Journal of Plastic, Reconstructive and Aesthetic Surgery

Volumn 63, Issue 7, 2010, Pages 1209-1216

  Zhang, Guo You ^a   Cheng, Tao ^b   Zheng, Ming Hua ^a   Yi, Cheng Gang ^c   Pan, Hua ^c   Li, Zhi Jie ^a   Chen, Xing Long ^a   Yu, Qing ^a   Jiang, Liang Fu ^a   Zhou, Fei Ya ^a   Li, Xiao Yang ^a   Yang, Jing Quan ^a   Chu, Ting Gang ^a   Gao, Wei Yang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Collagen I; Dermal fibrosis; Fibronection; Peroxisome Proliferator Activated Receptor ; Transforming growth factor 1; Troglitazone

Indexed keywords

COLLAGEN TYPE 1; FIBRONECTIN; LACTATE DEHYDROGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; TRANSFORMING GROWTH FACTOR BETA1; TROGLITAZONE;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST CULTURE; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN FIBROBLAST; WESTERN BLOTTING;

CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CHROMANS; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBRONECTINS; HUMANS; HYPOGLYCEMIC AGENTS; L-LACTATE DEHYDROGENASE; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77953294000     PISSN: 17486815     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bjps.2009.06.032     Document Type: Article

References (22)

1. Babu M., Diegelmann R., and Oliver N. Fibronectin is overproduced by keloid fibroblasts during abnormal wound healing. Mol Cell Biol 9 (1989) 1642-1650
2. Kischer C.W., and Hendrix M.J. Fibronectin in hypertrophic scars and keloids. Cell Tissue Res 231 (1983) 29-37
3. Ghahary A., Shen Y.J., Scott P.G., et al. Enhanced expression of mRNA for transforming growth factor-beta, type I and type III procollagen in human post-burn hypertrophic scar tissues. J Lab Clin Med 122 (1993) 465-473
4. Balza E., Borsi L., Allemanni G., et al. Transforming growth factor beta regulates the levels of different fibronectin isoforms in normal human cultured fibroblasts. FEBS Lett 228 (1988) 42-44
5. Rosenfield R.L., Deplewski D., and Greene M.E. Peroxisome proliferator-activated receptors and skin development. Horm Res 54 (2000) 269-274
6. Routh R.E., Johnson J.H., and McCarthy K.J. Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. Kidney Int 61 (2002) 1365-1376
7. Zheng F., Fornoni A., Elliot S.J., et al. Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Renal Physiol 282 (2002) F639-F648
8. Galli A., Crabb D.W., Ceni E., et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122 (2002) 1924-1940
9. Kon K., Ikejima K., Hirose M., et al. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 291 (2002) 55-61
10. Miyahara T., Schrum L., Rippe R., et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275 (2000) 35715-35722
11. Masamune A., Kikuta K., Satoh M., et al. Ligands of peroxisome proliferator-activated receptor-gamma block activation of pancreatic stellate cells. J Biol Chem 277 (2002) 141-147
12. McCarthy K.J., Routh R.E., Shaw W., et al. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 58 (2000) 2341-2350
13. Jia D.M., and Otsuki M. Troglitazone stimulates pancreatic growth in normal rats. Pancreas 24 (2002) 303-312
14. Varga J., Rosenbloom J., and Jimenez S.A. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 247 (1987) 597-604
15. Zhang G.Y., Yi C.G., Li X., et al. Inhibition of vascular endothelial growth factor expression in keloid fibroblasts by vector-mediated vascular endothelial growth factor shRNA: a therapeutic potential strategy for keloid. Arch Dermatol Res 300 (2008) 177-184
16. Ghosh A.K., Bhattacharyya S., Lakos G., et al. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 50 (2004) 1305-1318
17. Wang W., Liu F., and Chen N. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists attenuate the profibrotic response induced by TGF-beta1 in renal interstitial fibroblasts. Mediators Inflamm 2007 (2007) 62641
18. Yavrom S., Chen L., Xiong S., et al. Peroxisome proliferator-activated receptor gamma suppresses proximal alpha1(I) collagen promoter via inhibition of p300-facilitated NF-I binding to DNA in hepatic stellate cells. J Biol Chem 280 (2005) 40650-40659
19. Guo B., Koya D., Isono M., et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. Diabetes 53 (2004) 200-208
20. Bauer B.S., Tredget E.E., Marcoux Y., et al. Latent and active transforming growth factor beta1 released from genetically modified keratinocytes modulates extracellular matrix expression by dermal fibroblasts in a coculture system. J Invest Dermatol 119 (2002) 456-463
21. Parrelli J.M., and Meisler N. Abrogation of the fibrotic effect of transforming growth factor-beta in dermal wound healing. Wound Repair Regen 5 (1997) 136-140
22. Li Y., Wen X., Spataro B.C., et al. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists. J Am Soc Nephrol 17 (2006) 54-65